Quantcast

Latest atopic dermatitis Stories

2009-11-20 14:40:23

Scientists of Helmholtz Zentrum Mnchen and the Center of Allergy and Environment (ZAUM) of Technische Universität Mnchen have discovered a new type of immune cells - the Th22 cells - which can protect the body against inflammation and aid in tissue repair. In the current online issue of the Journal of Clinical Investigation, Dr. Stefanie Eyerich and Dr. Kilian Eyerich together with their colleagues from Imperial College London and Istituto Dermopatico dell'Immacolata in Rome, present...

2009-11-17 11:28:46

A new type of immune cell that can be out of control in certain chronic inflammatory diseases, worsening the symptoms of conditions like psoriasis and asthma, is described for the first time this week in the Journal of Clinical Investigation. The authors of the study, from Imperial College London, the Istituto Dermopatico dell'Immacolata in Rome and the Center of Allergy and Environment (ZAUM) in Munich, hope their discovery could lead to new treatments for these diseases that would bring the...

2009-10-06 14:02:51

Vaccination can lower children's risk of allergy. Cathleen Muche-Borowski and her coauthors present a clinical practice guideline for allergy prevention in the current issue of Deutsches Óžrzteblatt International (Dtsch Arztebl Int 2009; 106[39]: 625-31). Allergic diseases are becoming increasingly common in Western industrialized countries. As there is still no etiologically based treatment of allergic asthma, hay fever, or atopic eczema, the prevention of these...

2009-08-11 09:56:00

KNOXVILLE, Tenn., Aug. 11 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. (OTC BB: PVCT) reports on its year-to-date clinical and corporate accomplishments in a letter to shareholders from Craig Dees, Ph.D., CEO of Provectus. To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/pvct/39628/ Dear Shareholders: I am pleased to report that 2009 has already been a year of continued progress and excitement for Provectus. Our clinical trials for both PV-10 and...

2009-08-03 09:16:00

CHICAGO, Aug. 3 /PRNewswire/ -- Known medically as atopic dermatitis (AD), eczema is characterized by dry, itchy skin and rashes.(1) Scratching the affected area of skin may result in redness, swelling, scaling, cracking, weeping of clear fluid, and crusting of the skin.(2) Immuno-modulators called topical calcineurin (cal-SEE-nur-in) inhibitors (TCIs) can be effective treatments for patients with mild, moderate or severe eczema(3) who fail to respond adequately to first-line prescription...

2009-07-29 13:00:00

BOSTON, July 29 /PRNewswire-USNewswire/ -- Despite having access to some of the best health care in the world, many Americans with the most common form of eczema, known as atopic dermatitis, have sought relief from "alternative medicines." However, dermatologists caution that patients seeking alternative treatments to alleviate symptoms of this common, chronic, inflammatory skin disease marked by red, itchy rashes, risk developing more severe symptoms by delaying treatment. At the...

2009-07-03 07:00:00

TURKU, Finland, July 3 /PRNewswire/ -- BioCis Pharma Ltd., a privately held drug development company with its headquarters in Turku, Finland, announced positive results from its Phase IIa clinical trial of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology. This double-blind, placebo-controlled study, conducted in Finland, included 13 patients with mild to moderate atopic dermatitis who applied the ProtoCure emulsion cream to the affected skin areas twice daily...

2009-06-25 08:44:18

Eczema patients at risk for serious viral infections have more severe disease, are more likely to be allergic to food and other allergens, and have a frequent history of staph infections, according to researchers at National Jewish Health and other institutions in the NIH-funded Atopic Dermatitis Vaccinia Network. The findings, published June 22 in the online version of The Journal of Allergy and Clinical Immunology, could help identify people at risk for serious complications of smallpox...

2009-05-25 07:58:52

Researchers from the La Jolla Institute for Allergy & Immunology have pinpointed the cellular defect that increases the likelihood, among eczema sufferers, of developing eczema vaccinatum, a severe and potentially fatal reaction to the smallpox vaccine. The research, conducted in mouse models, was funded under a special research network created by the National Institutes of Health in 2004. The network is working toward the development of a new smallpox vaccine that could be administered...

2009-05-11 07:00:00

PACKAGING MORE EASILY IDENTIFIABLE YET STILL A SERIOUS MOISTURIZER MINNEAPOLIS, May 11 /PRNewswire/ -- Upsher-Smith has revamped its AmLactin(R) family of moisturizers packaging to feature more appealing labels. Just in time for summer, dry skin sufferers can now find relief in style. With vibrant colors and easy to use packaging, any of the AmLactin(R) products are perfect to grab and go. The sleek and smooth design of the new bottles and tubes is dually colored in white and light shades of...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related